Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neuphoria Therapeutics (NEUP) Operating Leases (2020 - 2025)

Neuphoria Therapeutics (NEUP) has disclosed Operating Leases for 5 consecutive years, with $19322.0 as the latest value for Q1 2025.

  • On a quarterly basis, Operating Leases changed N/A to $19322.0 in Q1 2025 year-over-year; TTM through Mar 2025 was $19322.0, a N/A change, with the full-year FY2023 number at $243603.0, down 36.26% from a year prior.
  • Operating Leases was $19322.0 for Q1 2025 at Neuphoria Therapeutics, down from $49818.0 in the prior quarter.
  • In the past five years, Operating Leases ranged from a high of $382188.6 in Q2 2022 to a low of $19322.0 in Q1 2025.
  • A 4-year average of $156514.3 and a median of $89469.0 in 2024 define the central range for Operating Leases.
  • Biggest YoY gain for Operating Leases was 36.74% in 2023; the steepest drop was 36.74% in 2023.
  • Neuphoria Therapeutics' Operating Leases stood at $382188.6 in 2022, then tumbled by 36.74% to $241774.0 in 2023, then plummeted by 79.39% to $49818.0 in 2024, then crashed by 61.21% to $19322.0 in 2025.
  • Per Business Quant, the three most recent readings for NEUP's Operating Leases are $19322.0 (Q1 2025), $49818.0 (Q4 2024), and $89469.0 (Q3 2024).